Saturday, March 29, 2025
Russia’s Cancer Vaccine Shows 100% Success in Trials, But Public Access Still Uncertain
Moscow, September 7, 2025 – Russia has announced a major breakthrough in the fight against cancer. A new mRNA-based vaccine, called Entromix, has demonstrated 100% effectiveness in clinical trials. The vaccine was jointly developed by the Russian Ministry of Health’s Radiology Center and the Institute of Molecular Biology.
The vaccine uses technology similar to that of COVID-19 vaccines. It employs four harmless viruses to target and destroy cancerous tumors. In addition, it boosts the patient’s immune system, enabling it to fight cancer more effectively.
During trials on 48 participants, the vaccine showed no serious side effects. It successfully destroyed cancer cells and reduced tumor size, with some patients experiencing a complete elimination of cancer.
Despite these highly promising results, the vaccine is not yet available to the general public. It is currently awaiting final approval from Russia’s Ministry of Health. Only after authorization will it be rolled out for wider use.
If granted approval, Entromix could mark a significant milestone in cancer treatment, offering new hope to millions of patients worldwide.
